Effectiveness and weight effects of open-label lammotrigine with and without concomitant psychotropic medications in patients with bipolar I disorder

MedGenMed Medscape General Medicine

Volumn 9, Issue 2, 2007, Pages

  ZarZar, Michael N ^a   Graham, Jay ^b   Roberts, Jeremy ^b   Thompson, Thomas ^b   Nanry, Kevin ^b  

^a Glenwood Psychiatric Associates   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; CARBAMAZEPINE; CITALOPRAM; CLONAZEPAM; LAMOTRIGINE; LITHIUM; NEUROLEPTIC AGENT; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; PSYCHOTROPIC AGENT; QUETIAPINE; VALPROIC ACID; ANALGESIC AGENT; TRIAZINE DERIVATIVE;

ADJUVANT THERAPY; ADULT; ARTICLE; BIPOLAR I DISORDER; BODY MASS; BODY WEIGHT; CLINICAL EFFECTIVENESS; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DIZZINESS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MANIA; MENTAL DISEASE; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; OPEN STUDY; OUTPATIENT CARE; PATIENT SATISFACTION; POST HOC ANALYSIS; QUALITY OF LIFE; QUESTIONNAIRE; SCORING SYSTEM; SIDE EFFECT; SYMPTOMATOLOGY; TREMOR; WEIGHT REDUCTION; BIPOLAR DISORDER; DRUG COMBINATION; DRUG EFFECT; METHODOLOGY; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; UNITED STATES;

ANALGESICS; BIPOLAR DISORDER; BODY WEIGHT; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; NORTH CAROLINA; PSYCHOTROPIC DRUGS; RISK ASSESSMENT; RISK FACTORS; TRIAZINES;

EID: 38449095961     PISSN: 15310132     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62:593-602.
2. Ghaemi SN, Soldani F, Hsu DJ. Evidence-based pharmacotherapy of bipolar disorder. Int J Neuropsychopharmacol. 2003;6:303-308.
3. Hirschfeld RMA, Bowden CL, Gitlin MJ, et al. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry. 2002;159(suppl 4): 1-50.
4. Keck PE Jr, Calabrese JR, McQuade RD, et al. A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J Clin Psychiatry. 2006;67:626-637.
5. Tohen M, Chengappa NR, Suples T, et al. Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone. Br J Psychiatry. 2004;184:337-345.
6. Tohen M, Calíbrese JR, Sachs GS, et al. Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. Am J Psychiatry. 2006;163:247-256.
7. Lamictal (lamotrigine) tablets [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2005.
8. Goodwin GM, Bowden CL, Calabrese JR, et al. A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. J Clin Psychiatry. 2004;65:432-441.
9. Bowden CL, Calabrese JR, Sachs G, et al, and the Lamictal 606 Study Group. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry. 2003;60:392-400.
10. Calabrese JR, Bowden CL, Sachs G, et al, and the Lamictal 605 Study Group. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry. 2003;64:1013-1024.
11. Calabrese JR, Suppes T, Bowden CL, et al; for the Lamictal 614 Study Group. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. J Clin Psychiatry. 2000;61:841-850.
12. Biton V, Mirza W, Montouris G, Vuong A, Hammer AE, Barrett PS. Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy. Neurology. 2001;56:172-177.
13. Devinsky O, Vuong A, Hammer A, Barrett PS. Stable weight during lamotrigine therapy: a review of 32 studies. Neurology. 2000;54:973-975.
14. Zyprexa (olanzapine) tablets [package insert]. Indianapolis, Ind: Eli Lilly and Company; 2006.
15. Blanco C, Laje G, Olfson M, Marcus SC, Pincus HA. Trends in the treatment of bipolar disorder by outpatient psychiatrists. Am J Psychiatry. 2002;159:1005-1010.
16. Ketter TA, Greist JH, Graham JA, Roberts JN, Thompson TR, Nanry KP. The effect of dermatologic precautions on the incidence of rash with addition of lamotrigine in the treatment of bipolar I disorder. J Clin Psychiatry. 2006;67:400-406.
17. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994.
18. Spearing MK, Post RM, Leverich GS, Brandt D, Nolen W. Modification of the Clinical Global Impressions (CGI) scale for use in bipolar illness (BP): the CGI-BP. Psychiatry Res. 1997;73:159-171.
19. Ritsner M, Kurs R, Gibel A, Ratner Y, Endicott J. Validity of an abbreviated quality of life enjoyment and satisfaction questionnaire (Q-LES-Q-18) for schizophrenia, schizoaffective, and mood disorder patients. Qual Life Res. 2005:14:1693-1703.
20. Kennedy SH, Rapaport MH, Reimherr FW, Davis KH. Effects of lamotrigine on quality of life in patients with bipolar I disorder. Program and abstracts of the Fifth International Conference on Bipolar Disorder; June 12-14, 2003; Pittsburgh, Pennsylvania.
21. Calabrese JR, Keck PE, Jr, Macfadden W, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry. 2005;162:1351-1360.
22. Elmslie JL, Silverstone JT, Mann JI, Williams SM, Romans SE. Prevalence of overweight and obesity in bipolar patients. J Clin Psychiatry. 2000;61:179-184.
23. Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation. 1983;67:968-977.
24. Angel A, Roncari DA. Medical complications of obesity. Can Med Assoc J. 1978; 119:1408-1411.
25. Pi-Sunyer FX. Medical hazards of obesity. Ann Intern Med. 1993;119(7 Pt 2):655-660.
26. Fagiolini A, Kupfer DJ, Houck PR, Novick DM, Frank E. Obesity as a correlate of outcome in patients with bipolar I disorder. Am J Psychiatry. 2003;160:112-117.
27. Bowden CL. Valproate. Bipolar Disord. 2003;5:189-202.
28. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;156:1686-1696.
29. Rudorfer MV, Manji HK, Potter WZ. Comparative tolerability profiles of the newer versus older antidepressants. Drug Saf. 1994;10:18-46.
30. Silverstone T. Moclobemide vs. imipramine in bipolar depression: a multicentre double-blind clinical trial. Acta Psychiatr Scand. 2001;104:104-109.
31. Merideth C, Southard CK. A double-blind, placebo-controlled evaluation of lamotrigine for obesity. Program and abstracts of the American Psychiatric Association Annual Meeting; May 21-26, 2005; Atlanta, Georgia.
32. Ginsberg LD, Bowden CL, Calabrese JR, Sachs GS, Ketter TA. Effects of mood stabilizers on body weight in bipolar I disorder. Program and abstracts of the American Psychiatric Association Annual Meeting; May 17-22, 2003; San Francisco, California.